scholarly journals GLYCEMIC CONTROL MODIFIES THE ASSOCIATION BETWEEN MICROALBUMINURIA AND C-REACTIVE PROTEIN IN TYPE 2 DIABETES MELLITUS

2020 ◽  
pp. 4-5
Author(s):  
Krishkumar A. Jivani
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Diabetes Mellitus Patient ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Type 2 Diabetics ◽  
Group 2

BACKGROUND: HbA1c is most commonly used parameter for glycemic control in type 2 diabetes mellitus patient. AIM The aim of the study was to evaluate whether any association exists between C-reactive protein and microalbuminuria in well controlled and poorly controlled Type 2 DM patients. METHOD : In this study, we included total 90 patients of type 2 Diabetes Mellitus admitted in GKGH , Bhuj during the period from Aug. 2018 to June 2019. The subjects were divided into two groups according to glycemic control as Group 1(Poorly controlled Diabetics) and Group 2( Well controlled Diabetics ) The groups 1 and 2 (based on Glycemic control) were further divided into 3 subgroups A, B and C (based on CRP level) with 15 subjects in each of these six subgroups. RESULT: Subjects with poor glycemic control had elevated values of MAU at all comparative levels of CRP. Further, it was shown that the level of MAU increased considerably with increasing level of CRP. CONCLUSION : There is a significant positive correlation between the level of MAU and CRP status in poorly controlled Type 2 diabetics.

scholarly journals C-reactive protein and glycemic control in adults with type 2 diabetes mellitus

2016 ◽  
Vol 2 ◽  
pp. 10-13
Author(s):  
Arun Sasidharan ◽  
Ajoy Krishnamurthy ◽  
Sida Tagore ◽  
Tejavathi Nagaraj ◽  
H. N. Santosh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
C Reactive Protein ◽  
Reactive Protein

Glycemic Control Comparative of Metformin and Glimepiride in Monotherapy of Type 2 Diabetes Mellitus Patient at Islamic Jemursari Hospital Surabaya in 2018

2021 ◽  
Vol 71 (1) ◽  
pp. 24-29
Author(s):  
Rachma Putri Nariswari ◽  
Gwenny Ichsan Prabowo ◽  
Hermina Novida ◽  
Nurina Hasanatuludhhiyah
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Adult Population ◽  
Secondary Data ◽  
Diabetes Mellitus Patient ◽  
Significant Difference ◽  
Tissue Sensitivity

Introduction: Type 2 diabetes mellitus is caused by decreased tissue sensitivity to insulin. The prevalence of diabetes in the world has almost doubled since 1980, from 4.7% to 8.5% in adult population. Early diagnosis and treatment aimed at normalizing glycemic control are very important. The objective of this study was to evaluate and compare glycemic control of metformin and glimepiride in monotherapy of type 2 diabetes mellitus patients at Islamic Jemursari Hospital Surabaya. Method: This was a retrospective observational study using secondary data (medical record), include glycemic control (RPG) before and two months after receiving therapy of outpatients’ type 2 diabetes mellitus with metformin or glimepiride therapy in 2018. 96 samples were found that fit the inclusion criteria. The data were analyzed by Mann-Whitney test. Result: Most patients were female, aged 50-69 years old, and dosage of metformin therapy 1500 mg/day or glimepiride therapy 2 mg/day. There was no significant difference (p>0.05) of glycemic control (RPG) of metformin compared to glimepiride therapies in type 2 diabetes mellitus patients at Islamic Jemursari Hospital Surabaya in 2018. Conclusion: Metformin and glimepiride were not significantly different in glycemic control (RPG). There were patients with RPG >200 mg/dl after two months of metformin or glimepiride therapy.  

scholarly journals Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Feng Tian ◽  
Zhigang Zheng ◽  
Damin Zhang ◽  
Si He ◽  
Jie Shen
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
C Reactive Protein ◽  
Alcoholic Fatty Liver ◽  
Reactive Protein ◽  
Alcoholic Fatty Liver Disease

Type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) is difficult to treat. The present study explored the efficacy of (liraglutide) Lira in treating T2DM complicated with NAFLD. A total of 127 patients suffering from T2DM complicated with NAFLD were enrolled in the present study, and randomly assigned to a Lira group (liraglutide injection: 0.6–1.2 mg/day, 12 weeks, n=52) or a Metformin (Met) group (oral metformin: 1000–1500 mg/day, 12 weeks, n=75). During the treatment phase, the values for fasting plasma glucose (FPG), 2 h plasma glucose (2hPG), glycated hemoglobin (HbA1c), aspartate aminotransferase (AST)/alanine aminotransferase (ALT), and adiponectin (APN) decreased in both the Lira and Met groups, and the levels of Δ2hPG, ΔAST/ALT, and ΔAPN in the Lira group were significantly lower than those in the Met group. The values for total cholesterol (TC), triglycerides (TG), low-and high-density lipoproteins (LDL and HDL), ALT, AST, weight, body mass index (BMI), waist to hip ratio (WHR), and C-reactive protein were markedly increased in both groups, and levels of ΔAST, ΔALT, Δweight, ΔBMI, ΔWHR, and ΔCRP (C-reactive protein) in the Lira group were significantly higher than those in the Met group. An analysis of treatment efficacy showed that liraglutide was better than metformin in its ability to significantly decrease the ALT levels in patients with combined T2DM and NAFLD. Furthermore, liraglutide was more effective than metformin at ameliorating the severity of T2DM complicated with NAFLD, and produced its effects by alleviating liver inflammation and improving liver function.

Sign in / Sign up

Export Citation Format

Share Document